Primary Care Office-based Buprenorphine Treatment: Comparison of Heroin and Prescription Opioid Dependent Patients
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Prescription opioid dependence is increasing, but treatment outcomes with office-based buprenorphine/naloxone among these patients have not been described.
We compared demographic, clinical characteristics and treatment outcomes among 200 patients evaluated for entry into a trial of primary care office-based buprenorphine/naloxone treatment stratifying on those who reported exclusive heroin use (n = 124), heroin and prescription opioid use (n = 47), or only prescription opioid use (n = 29).
Compared to heroin-only patients, prescription-opioid-only patients were younger, had fewer years of opioid use, and less drug treatment history. They were also more likely to be white, earned more income, and were less likely to have Hepatitis C antibodies. Prescription-opioid-only patients were more likely to complete treatment (59% vs. 30%), remained in treatment longer (21.0 vs. 14.2 weeks), and had a higher percent of opioid-negative urine samples than heroin only patients (56.3% vs. 39.8%), all p values < .05. Patients who used both heroin and prescription opioids had outcomes that were intermediate between heroin-only and prescription-opioid-only patients.
Individuals dependent on prescription opioids have an improved treatment response to buprenorphine/naloxone maintenance in an office-based setting compared to those who exclusively or episodically use heroin.
- Results from the 2003 National Survey on Drug Use and Health: National findings (DHHS Publication No. SMA 04-3964, NHSDA Series H-25). Substance Abuse and Mental Health Services Administration, Rockville, MD
- Potter, JS, Hennessy, G, Borrow, JA, Greenfield, SF, Weiss, RD (2004) Substance use histories in patients seeking treatment for controlled-release oxycodone dependence. Drug Alcohol Depend 76: pp. 213-215 CrossRef
- Simoni-Wastila, L, Strickler, G (2004) Risk factors associated with problem use of prescription drugs. Am J Public Health 94: pp. 266-268 CrossRef
- Simoni-Wastila, L, Ritter, G, Strickler, G (2004) Gender and other factors associated with the nonmedical use of abusable prescription drugs. Subst Use Misuse 39: pp. 1-23 CrossRef
- Fiellin, DA, Pantalon, MV, Pakes, J, O’Connor, PG, Chawarski, M, Schottenfeld, RS (2002) Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 28: pp. 231-241 CrossRef
- Stein, MD, Cioe, P, Friedmann, PD (2005) Buprenorphine retention in primary care. J Gen Intern Med 20: pp. 1038-1041 CrossRef
- Turner, BJ, Laine, C, Lin, YT, Lynch, K (2005) Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med 165: pp. 1769-1776 CrossRef
- Krantz, MJ, Mehler, PS (2004) Treating opioid dependence. Growing implications for primary care. Arch Intern Med 164: pp. 277-288 CrossRef
- Diagnostic and statistical manual of mental disorders. American Psychiatric Association, Washington, DC
- Radloff, LS (1977) The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1: pp. 385-401 CrossRef
- Knight, K, Halcom, M, Simpson, DD (1994) TCU psychosocial functioning and motivation scales: Manual on psychometric properties. Texas Christian University, Institute for Behavioral Research
- McLellan, AT, Kushner, H, Metzger, D (1992) The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 9: pp. 199-213 CrossRef
- Fiellin, D, Pantalon, MV, Chawarski, M (2006) Buprenorphine maintenance in primary care: a randomized controlled trial of counseling conditions and medication dispensing. N Engl J Med 355: pp. 365-374 CrossRef
- Hosmer, DW, Lemeshow, S (2000) Applied Logistic Regression. John Wiley & Sons, New York
- Fiellin, DA, O’Connor, PG, Chawarski, M, Pantalon, MV, Schottenfeld, RS (2002) Office versus narcotic treatment program-based buprenorphine for opioid dependence. Drug Alcohol Depend 66: pp. S55-S56
- Fudala, PJ, Bridge, TP, Herbert, S (2003) Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 349: pp. 949-958 CrossRef
- Fiellin, DA, O’Connor, PG (2002) New Federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med 137: pp. 688-692
- Sullivan, LE, Chawarski, M, O’Conner, PG, Schottenfeld, RS, Fiellin, DA (2005) The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering treatment?. Drug Alcohol Depend 79: pp. 113-116 CrossRef
- McLeod CC, Kissin WB, Stanton A, Sonnefeld J. 30-day outcomes for buprenorphine patients treated by a national sample of qualified physicians. College on Problems of Drug Dependence. Orlando, FL; 2005.
- Primary Care Office-based Buprenorphine Treatment: Comparison of Heroin and Prescription Opioid Dependent Patients
Journal of General Internal Medicine
Volume 22, Issue 4 , pp 527-530
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- buprenorphine/therapeutic use
- primary health care
- opioid-related disorders
- Industry Sectors
- Author Affiliations
- 1. Department of Psychiatry, Yale University School of Medicine, 219S CMHC-SAC 34 Park St., New Haven, Connecticut, 06519, USA
- 2. Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA